1 Supplemental Methods and Results

2 Validation of C. coli qPCR

3 A referable clinical test was not available for the detection of Campylobacter coli using 4 quantitative PCR (gPCR) from rectal swabs, as was available for the detection of C. jejuni. Initial 5 tests for primer selection and validation of standard curves were required, as well as the validation of multiplexing capability with the Xeno[™] Internal Control and OSM assays. Primer 6 7 and probe combinations selected for trial were cadF, ceuE, and glyA, based on previous publications.^{1,3,4,5} DNA extracted from a pure colony of *C. coli* (ATCC 49941) was used to 8 9 determine the ideal concentration of each primer-probe combination. CadF and ceuE combinations behaved similarly regardless of the concentration and 300 nM of each primer and 10 100 nM of each probe were selected as the concentrations for all future work. GlyA produced 11 12 poor amplification regardless of concentration (data not shown) and was removed from further 13 analysis. To select between cadF and ceuE, each primer-probe set was tested against a standard curve multiplexed with the Xeno[™] Internal Control assay. The Xeno[™] Internal Control 14 assay performed better in conjunction with the cadF primers and probe (Table S4), so cadF was 15 16 selected as the detection method for *C. coli* in the rhesus macaque fecal DNA samples. The *cadF*+ Xeno[™] Internal Control assay was also tested for inclusivity and exclusivity against other 17 18 common Campylobacter species. The assay detected four different strains of C. coli (BAA370, 19 BAA371, BAA1061, ATCC 49941), and displayed no amplification of DNA from two strains of C. 20 fetus venerealis (ATCC 19438, ATCC 33561), two strains of C. fetus fetus (ATCC 27374, ATCC 21 25936), or a strain of C. jejuni (ATCC 33560). The cadF assay was also multiplexed with the NHP OSM assay as above.² Each assay was tested at varying ratios of Campylobacter to 22 23 rhesus macaque DNA and the functionality of the three primers (*cadF/gyrA*, OSM, and Xeno™ 24 Internal Control) tested in triplicate (Table S5). Ultimately, these efforts resulted in a final reaction of 2 µL of each DNA sample and blank combined with 4.35 µL of nuclease-free water 25 (Invitrogen, Waltham, MA), 5 µL of Tagman Fast Virus 1-step Master Mix 4x (Thermo Fisher, 26

27 Cleveland, OH), 1 µL (300 nM) of forward and reverse primers for the C. coli cadF gene, 0.4 µL 28 (100 nM) of the probe for the C. coli cadF gene, 1 μ L of XenoTM Assay, and 2.5 μ L (1 μ M) forward and reverse primers for the NHP OSM gene, and 0.25 µL (100 nM) probe for the NHP 29 OSM gene, for a total reaction volume of 20 µL per sample. As with the C. jejuni reaction, each 30 31 set of reactions was run with a standard curve of known quantities of C. coli (ATCC 49941), 2 µL of nuclease-free water as a no-template negative control, 2 µL of DNA extracted from rhesus 32 macaque whole blood as a positive control for the OSM, and 2 µL Xeno[™] Internal Control DNA 33 as a positive control for the XenoTM Internal Control. The reaction parameters were identical to 34 35 the *C. jejuni gyrA* reaction.

36

37 Validation of C. coli and C. jejuni qPCR on archived samples

38 To assess the utility of the assays with respect to archived samples, validation trials to 39 mimic DNA extraction and qPCR from frozen swabs were performed using canine feces negative for Campylobacter species and then spiked with known guantities of C. coli. Swabs 40 were spiked and DNA immediately extracted on Day 0. A second set of swabs were spiked at 41 42 stored for 1 month at -80°C, and a third set was spiked and stored in Amies Remel™ 43 BactiSwab[™] Gel Collection and Transport Swab (Fisher Scientific, Waltham, MA) for 1 month at 44 -80°C. DNA extraction was performed on the second and third set on the same day after 30 days of freezing. DNA extract from all three sets of swabs were stored at -20°C and gPCR 45 performed on the same day. The assay behaved similarly at both time points, however there 46 47 was more variable detection limits in the freezer stored samples, particularly at C. coli concentrations \leq 26,000 CFU/mL (Figure S1). Similar methods were applied to the *C. jejuni* 48 49 assay (data not shown). Given these results and logistic limitations to performing same day DNA extractions on freshly collected swabs from the rhesus macaques, a higher cycle number 50 (45) was selected to avoid classifying an animal shedding \leq 26,000 CFU/mL as negative, 51

- 52 limiting potential misclassification of animals which were positive as negative to those shedding
- 53 ≤ 2,600 CFU/mL.

55 Supplemental References

1. Best EL, Powell EJ, Swift C, Grant KA, Frost JA. Applicability of a rapid duplex real-time PCR

57 assay for speciation of Campylobacter jejuni and Campylobacter coli directly from culture plates.

- 58 *FEMS Microbiology Letters*. 2003;229: 237-241.
- 2. Bruce AG, Bakke AM, Thouless ME, Rose TM. Development of a real-time QPCR assay for
- 60 the detection of RV2 lineage-specific rhadinoviruses in macaques and baboons. *Virology*
- 61 *journal*. 2005;2: 1-12.
- 62 3. Leblanc-Maridor M, Beaudeau F, Seegers H, Denis M, Belloc C. Rapid identification and
- 63 quantification of Campylobacter coli and Campylobacter jejuni by real-time PCR in pure cultures
- and in complex samples. *BMC microbiology*. 2011;11: 1-16.
- 4. Tissier A, Denis M, Hartemann P, Gassilloud B. Development of a rapid and sensitive method
- 66 combining a cellulose ester microfilter and a real-time qPCR assay to detect Campylobacter
- 67 jejuni and Campylobacter coli in 20 liters of drinking water or low turbidity waters. *Applied and*
- 68 Environmental Microbiology. 2011.
- 5. Toplak N, Kovač M, Piskernik S, Možina SS, Jeršek B. Detection and quantification of
- 70 Campylobacter jejuni and Campylobacter coli using real-time multiplex PCR. Journal of applied
- 71 *microbiology*. 2012;112: 752-764.
- 72

74 Supplemental Tables and Figures

| | ceuE | qPCR | <i>cadF</i> qPCR | | |
|------------|-------|-------------------|------------------|-------------------|--|
| CFU/mL | ceuE | Xeno ^a | cadF | Xeno ^a | |
| | Ct | Ct | Ct | Ct | |
| 18,000,000 | 20.68 | 40.00 | 21.57 | 33.98 | |
| 1,800,000 | 27.10 | 40.00 | 27.72 | 32.98 | |
| 180,000 | 31.62 | 39.59 | 32.19 | 34.11 | |
| 18,000 | 33.24 | 35.70 | 34.52 | 32.32 | |
| 1,800 | 36.52 | 35.74 | 38.92 | 32.77 | |
| 180 | 39.89 | 36.90 | 40.00 | 33.90 | |

Table S4: Average number of amplification cycles required to cross threshold for each primer settested in duplicate.

^aApplied Biosystems[™] VetMAX[™] Xeno[™] Internal Positive Control DNA and Assay. The Xeno[™] Internal Positive Control DNA is added to samples prior to extraction as an extraction and PCR inhibition control. Abbreviations: CFU/mL, colony forming units per millileter; qPCR, quantitative PCR; Ct, cycle threshold

77

- 78
- ---
- 79
- 80
- 81
- 82
- 83
- 84
- 85

Table S5: Average number of amplification cycles required to cross threshold for multiplexed qPCR assays tested in triplicate.

| C. coli cadF+OSM Assay | | | | | | | | | | | |
|------------------------|---------|------------------|-------------|----------|--------|--|--|--|--|--|--|
| | NHP DNA | <i>cadF</i> qPCR | | OSM qPCR | OSM St | | | | | | |
| CFU/mL | (ng/mL) | Ct | cadF St Dev | Ct | Dev | | | | | | |
| 25,200 | 0.158 | 32.39 | 0.13 | 31.60 | 0.28 | | | | | | |
| 2,520 | 0.158 | 35.53 | 0.18 | 31.87 | 0.28 | | | | | | |
| 252 | 0.158 | 45.00 | 0.00 | 31.68 | 0.12 | | | | | | |
| 25,200 | 1.58 | 32.13 | 0.37 | 28.48 | 0.03 | | | | | | |
| 2,520 | 1.58 | 35.33 | 0.82 | 28.62 | 0.09 | | | | | | |
| 252 | 1.58 | 45.00 | 0.00 | 28.78 | 0.18 | | | | | | |

| 25,200 | 15.8 | 32.03 | 0.17 | 25.55 | 0.19 | | | | | | |
|---|--------------|------------------|--------------------|-----------------|--------|--|--|--|--|--|--|
| 2,520 | 15.8 | 40.04 | 4.38 | 25.28 | 0.01 | | | | | | |
| 252 | 15.8 | 45.00 | 0.00 | 25.31 | 0.07 | | | | | | |
| C. jejuni gyrA+OSM Assay | | | | | | | | | | | |
| | NHP DNA | <i>gyrA</i> qPCR | | <i>OSM</i> qPCR | OSM St | | | | | | |
| CFU/mL | (ng/mL) | Ct | gyrA St Dev | Ct | Dev | | | | | | |
| 6,400 | 0.158 | 33.86 | 0.32 | 31.16 | 0.21 | | | | | | |
| 640 | 0.158 | 39.02 | 5.18 | 31.04 | 0.15 | | | | | | |
| 64 | 0.158 | 45.00 | 0.00 | 30.89 | 0.26 | | | | | | |
| 6,400 | 1.58 | 34.17 | 0.73 | 27.66 | 0.51 | | | | | | |
| 640 | 1.58 | 39.20 | 5.14 | 28.17 | 0.17 | | | | | | |
| 64 | 1.58 | 45.00 | 0.00 | 28.43 | 0.10 | | | | | | |
| 6,400 | 15.8 | 33.64 | 0.15 | 24.81 | 0.05 | | | | | | |
| 640 | 15.8 | 38.69 | 5.46 | 24.88 | 0.10 | | | | | | |
| 64 | 15.8 | 45.00 | 0.00 | 24.59 | 0.18 | | | | | | |
| <i>cadF/gyrA+OSM</i> +Xeno™ Multiplex Assaysª | | | | | | | | | | | |
| | | | gyrA qPCR | | | | | | | | |
| <i>cadF</i> qPCR Ct | | 23.82 | Ct | 14.67 | | | | | | | |
| <i>cadF</i> St Dev | | 1.61 | <i>gyrA</i> St Dev | 0.50 | | | | | | | |
| | | | OSM qPCR | | | | | | | | |
| OSM qPCR Ct⁵ | | 29.63 | Ct⁵ | 30.07 | | | | | | | |
| | OSM St Dev | 0.61 | OSM St Dev | 0.08 | | | | | | | |
| | Xeno™ Ct | 30.77 | Xeno™ Ct | 32.16 | | | | | | | |
| | | | Xeno™ St | | | | | | | | |
| | Xeno™ St Dev | 0.36 | Dev | 0.09 | | | | | | | |

^aBacterial DNA was obtained from direct boiling of several bacterial colonies following 48 hour incubation at 42°C.

^bNHP DNA concentration used for complete multiplex trials was 1.58 ng/mL.

Abbreviations: CFU/mL, colony forming units per millileter; NHP, non-human primate; OSM, non-human primate oncostatin M; St Dev, standard deviation

- 89
- ...
- 90
- 91

92 Figure S1: Validation of qPCR on DNA extracted from fresh and frozen canine fecal swabs

negative for *Campylobacter* sp. and spiked with a known concentration of *C. coli*. DNA was

extracted from the swabs directly after spiking (Day 0), following 30 days of freezing at -80°C in

no media (Day 30 without media), and following 30 days of freezing at -80°C in Amies Clear

96 media (Day 30 with media), and qPCR for *C. coli* performed as described.



97

98